126 related articles for article (PubMed ID: 33929528)
1. Rescreening Practices of Negative Papanicolaou Tests With Positive Human Papillomavirus Test Result.
Goyal A; Davey DD; Souers RJ; Tabbara SO; Goodrich K; Booth CN
Arch Pathol Lab Med; 2022 Jan; 146(1):78-83. PubMed ID: 33929528
[TBL] [Abstract][Full Text] [Related]
2. Human Papillomavirus Genotyping Testing Practice in 2014: Results of a College of American Pathologists National Survey.
Zhao C; Crothers BA; Ghofrani M; Li Z; Souers RJ; Hussain M; Fan F; Ocal IT; Goodrich K; Shen R; Davey DD;
Arch Pathol Lab Med; 2016 Dec; 140(12):1364-1370. PubMed ID: 27479334
[TBL] [Abstract][Full Text] [Related]
3. Prospective and retrospective review of gynecologic cytopathology: findings from the College of American Pathologists Gynecologic Cytopathology Quality Consensus Conference working group 2.
Brainard JA; Birdsong GG; Elsheikh TM; Hartley DA; Naik K; Neal MH; Souers RJ; Henry MR
Arch Pathol Lab Med; 2013 Feb; 137(2):175-82. PubMed ID: 23368859
[TBL] [Abstract][Full Text] [Related]
4. NILM Pap slides from women 30 years of age and older with positive high-risk HPV DNA. Focused rescreening prior to report issuance, an enhanced quality control measure.
Cormier K; Schaaf M; Hamilton S; Tickman RJ; Perez-Reyes N; Sturgis CD
Am J Clin Pathol; 2014 Apr; 141(4):494-500. PubMed ID: 24619749
[TBL] [Abstract][Full Text] [Related]
5. Negative computer-imaged ThinPrep Pap test and positive hybrid capture2 HPV co-testing results: A quality assurance review.
Rao R; Molina D; Halligan AM; Vakil B; Alperstein SA; Hoda RS
Diagn Cytopathol; 2015 Sep; 43(9):763-9. PubMed ID: 26173579
[TBL] [Abstract][Full Text] [Related]
6. Rescreening of high-risk HPV positive Papanicolaou tests initially screened as negative is a low yield procedure in the era of HPV genotyping.
Narkcham S; Mody DR; Jones A; Thrall MJ
J Am Soc Cytopathol; 2021; 10(6):558-564. PubMed ID: 34103275
[TBL] [Abstract][Full Text] [Related]
7. The value of monitoring human papillomavirus DNA results for Papanicolaou tests diagnosed as atypical squamous cells of undetermined significance: a College of American Pathologists Q-Probes study of 68 institutions.
Tworek JA; Jones BA; Raab S; Clary KM; Walsh MK
Arch Pathol Lab Med; 2007 Oct; 131(10):1525-31. PubMed ID: 17922588
[TBL] [Abstract][Full Text] [Related]
8. Navigating Practice Issues Related to the Unsatisfactory Cervicovaginal Papanicolaou Test: Survey Results of Laboratories Participating in the 2020 College of American Pathologists PAP Education Program.
Goyal A; Booth CN; Souers RJ; Tabbara SO; Roberson J; Henry MR; Sundling KE; Goodrich K; Nguyen L
Arch Pathol Lab Med; 2024 Jan; 148(1):48-54. PubMed ID: 37074866
[TBL] [Abstract][Full Text] [Related]
9. Previous Papanicolaou and Hybrid Capture 2 human papillomavirus testing results of 5699 women with histologically diagnosed cervical intraepithelial neoplasia 2/3.
Wu T; Chen X; Zheng B; Li J; Xie F; Ding X; Zeng Z; Zhao C
J Am Soc Cytopathol; 2019; 8(4):206-211. PubMed ID: 31272603
[TBL] [Abstract][Full Text] [Related]
10. Negative Pap tests in women with high-grade cervical lesions on follow-up biopsies: Contributing factors and role of human papillomavirus genotyping.
Goodman S; Mody RR; Coffey D; Gorman BK; Luna E; Armylagos D; Schwartz MR; Mody DR; Ge Y
Diagn Cytopathol; 2018 Mar; 46(3):239-243. PubMed ID: 29230975
[TBL] [Abstract][Full Text] [Related]
11. Knowledge of the HPV status biases cytotechnologists' interpretation of Pap tests originally diagnosed as negative for intraepithelial lesion or malignancy.
Doxtader EE; Brainard JA; Underwood D; Chute DJ
Cancer Cytopathol; 2017 Jan; 125(1):60-69. PubMed ID: 27731938
[TBL] [Abstract][Full Text] [Related]
12. Focused rescreening of NILM Pap slides from women ≥ 30 years of age with positive high risk HPV DNA: an enhanced quality control measure.
Sturgis CD; Schaaf MR; Tickman RJ
Diagn Cytopathol; 2013 May; 41(5):399-403. PubMed ID: 22351303
[TBL] [Abstract][Full Text] [Related]
13. Clinical performance of the Food and Drug Administration-Approved high-risk HPV test for the detection of high-grade cervicovaginal lesions.
Zhou H; Mody RR; Luna E; Armylagos D; Xu J; Schwartz MR; Mody DR; Ge Y
Cancer Cytopathol; 2016 May; 124(5):317-23. PubMed ID: 26774025
[TBL] [Abstract][Full Text] [Related]
14. Human papillomavirus testing and reporting rates in 2012: results of a College of American Pathologists national survey.
Zhao C; Moriarty AT; Ghofrani M; Husain M; Tambouret RH; Laucirica R; Laser A; Fischer A; Ocal IT; Souers RJ; Russell DK; Fan F; Crothers BA
Arch Pathol Lab Med; 2015 Jun; 139(6):757-61. PubMed ID: 25436905
[TBL] [Abstract][Full Text] [Related]
15. Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results.
Manos MM; Kinney WK; Hurley LB; Sherman ME; Shieh-Ngai J; Kurman RJ; Ransley JE; Fetterman BJ; Hartinger JS; McIntosh KM; Pawlick GF; Hiatt RA
JAMA; 1999 May; 281(17):1605-10. PubMed ID: 10235153
[TBL] [Abstract][Full Text] [Related]
16. Implementation of the ThinPrep Imaging System in a tertiary military medical center.
Duby JM; DiFurio MJ
Cancer; 2009 Aug; 117(4):264-70. PubMed ID: 19536887
[TBL] [Abstract][Full Text] [Related]
17. Monitoring and ordering practices for human papillomavirus in cervical cytology: findings from the College of American Pathologists Gynecologic Cytopathology Quality Consensus Conference working group 5.
Booth CN; Bashleben C; Filomena CA; Means MM; Wasserman PG; Souers RJ; Henry MR
Arch Pathol Lab Med; 2013 Feb; 137(2):214-9. PubMed ID: 23368863
[TBL] [Abstract][Full Text] [Related]
18. Bethesda 2014 Implementation and Human Papillomavirus Primary Screening: Practices of Laboratories Participating in the College of American Pathologists PAP Education Program.
Davey DD; Souers RJ; Goodrich K; Mody DR; Tabbara SO; Booth CN
Arch Pathol Lab Med; 2019 Oct; 143(10):1196-1202. PubMed ID: 31021657
[TBL] [Abstract][Full Text] [Related]
19. HPV detection rates and histopathologic follow-up of patients with HSIL cytology in a large academic women's hospital laboratory.
Ashman D; Zhang H; Li J; Austin M; Wang T; Pradhan D; Zhao C
J Am Soc Cytopathol; 2020; 9(6):550-555. PubMed ID: 32475726
[TBL] [Abstract][Full Text] [Related]
20. Use of a high-risk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study.
Zorzi M; Del Mistro A; Farruggio A; de'Bartolomeis L; Frayle-Salamanca H; Baboci L; Bertazzo A; Cocco P; Fedato C; Gennaro M; Marchi N; Penon MG; Cogo C; Ferro A
BJOG; 2013 Sep; 120(10):1260-7; discussion 1267-8. PubMed ID: 23786222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
